Novel candidate acquired from Ganymed in 2016 moves closer to first approval filing anywhere for a CLDN18-targeting antibody, and as a potential competitor for Opdivo in HER2-negative gastric cancer, following positive top-line Phase III results in the first-line combo setting. Results from GLOW trial in combination with CAPOX also awaited.

California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.

Gilead’s Kite is the current leader in CAR-T, but is looking for ways to stay ahead of competitors and find safer and more effective next-generation therapies.

The long-standing SillaJen saga in Korea appears close to ending following a decision that the company can maintain its stock market listing. Shares in the oncolytic virus firm surged by their daily limit on the resumption of trading, on hopes it will be able to get back on track.